Weight-loss drugs have change into a hot topic as public heath authorities and pharmaceutical corporations seek to seek out solutions to the growing global obesity epidemic.
Florian Gaertner | Photothek | Getty Images
An oral drug made by Pfizer causes the same amount of weight reduction as, and works quicker than, rival Novo Nordisk‘s blockbuster injection Ozempic, in keeping with results from a phase two clinical trial released Monday.
The outcomes were presented at a medical conference late last yr. But JAMA Network only now’s releasing the complete peer-reviewed study.
Pfizer’s trial followed 411 adults with Type 2 diabetes who either took the corporate’s pill, danuglipron, twice a day or a placebo.Â
Patients who took a 120-milligram version of danuglipron lost around 10 kilos over the course of 16 weeks, the study found.
That compares with a phase three clinical trial on Ozempic, which found that adults who took a 1-milligram version of the injection lost around 9.9 kilos on average over 30 weeks. Patients take that shot once every week.Â
The outcomes suggest danuglipron could also be as effective for weight as Ozempic over a shorter time period.Â
Pfizer’s drug also could offer a bonus as an oral treatment option fairly than a frequent injection.
Each danuglipron and Ozempic are a part of a category of medicine called glucagon-like peptide-1 antagonists.
They mimic a hormone produced within the gut called GLP-1, which signals to the brain when an individual is full.Â
The drugs may also help people manage Type 2 diabetes because they encourage insulin release from the pancreas, lowering blood sugar levels.
Recent York-based Pfizer is the most recent pharmaceutical company to dip into the blockbuster weight reduction drug market.Â
Novo Nordisk’s Ozempic and Wegovy catapulted to the national highlight in recent times for being weight reduction “miracles.”
Hollywood celebrities, social media influencers, and billionaire tech mogul Elon Musk have reportedly used the favored injections to do away with unwanted weight.Â
But experts say the medicines may further perpetuate a dangerous food plan culture that idealizes weight reduction and thinness.
Some patients who stop taking the drugs also complain a couple of weight rebound that’s difficult to regulate.
Greater than 2 in 5 adults have obesity, in keeping with the National Institutes of Health. About 1 in 11 adults have severe obesity.
